COMMUNIQUÉS West-GlobeNewswire

Vor Bio Doses First AML Patient with VCAR33 (ALLO) and Provides Corporate Update
17/01/2024
First patient dosed in company’s second clinical program with initial data expected in second half of 2024 Cash runway extended into second half of 2025 with clinical trials on track CAMBRIDGE, Mass., Jan. 17, 2024 ( [...]
Immatics Announces Proposed Public Offering
17/01/2024
Houston, Texas and Tuebingen, Germany, January 17, 2024 – Immatics N.V. (NASDAQ: IMTX, “Immatics”), a clinical-stage biopharmaceutical company active in the discovery and development of T cell-redirecting cancer [...]
Nextech Med Spa Software Launches Industry's Most Sophisticated Client Photo Functionalities
17/01/2024
TAMPA, Fla., Jan. 17, 2024 (GLOBE NEWSWIRE) -- Nextech today announced its med spa software now offers industry-leading photo management functionality for med spas that are ready to start the new year with new ways to [...]
Starton Therapeutics Announces STARTICLES Filing
17/01/2024
STARTICLES, referring to proprietary and novel solid-state particulates suspended within a drug-in-adhesive patch for delivery of active pharmaceutical ingredients (API) developed by Starton Therapeutics. STARTICLES is [...]
Oxurion Receives Transparency Notification from Atlas Special Opportunities LLC
17/01/2024
Regulated Information Leuven, BELGIUM – January 17, 2024 – 7:00 PM CET Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company headquartered in Leuven, today announced that, pursuant to Belgian Transparency [...]
EUROBIO SCIENTIFIC CONFIRME SON ELIGIBILITE AU DISPOSITIF PEA-PME
17/01/2024
EUROBIO SCIENTIFIC CONFIRME SON ELIGIBILITE AU DISPOSITIF PEA-PME Paris, le 17 janvier 2024 – 17h45 Eurobio Scientific (FR0013240934, ALERS, éligible PEA-PME), groupe français leader dans le diagnostic médical in vitro [...]
Eurobio Scientific : BILAN SEMESTRIEL S2 DU CONTRAT DE LIQUIDITE
17/01/2024
BILAN SEMESTRIEL S2 DU CONTRAT DE LIQUIDITE Paris, le 17 janvier 2024 – 17h45 Au titre du contrat de liquidité portant sur les actions de la société EUROBIO SCIENTIFIC (FR0013240934 – ALERS FP) confié à TP ICAP (Europe [...]
VIRBAC: Annual revenue growth of +4.9% thanks to record fourth-quarter activity at +11.5%
17/01/2024
KEY FIGURES Annual Revenue 2023 €1,246.9 million Growth at constant exchange rates and scope 1 +4.9% of which companion animals +3.5% farm animals +6.7% Growth at constant exchange rates +4.9% Overall change +2.5% 1 [...]
VIRBAC: Croissance du chiffre d’affaires annuel à +4,9% grâce à un niveau record d’activité au quatrième trimestre à +11,5%
17/01/2024
CHIFFRES CLÉS Chiffre d’affaires annuel 2023 1 246,9 M€ Croissance à taux de change et périmètre constants 1 +4,9% dont animaux de compagnie +3,5% animaux d’élevage +6,7% Croissance à taux de change constants +4,9% [...]
Postponement of the decision on the adoption of a sale plan (plan de cession) and the opening of judicial liquidation proceedings to January 31, 2024
17/01/2024
Postponement of the decision on the adoption of a sale plan ( plan de cession ) and the opening of judicial liquidation proceedings to January 31, 2024 Paris, France, January 17, 202 4 – 5:00 pm (CET) – Pixium Vision SA [...]
Report de la décision concernant l’arrêté d’un plan de cession et l’ouverture d’une procédure de liquidation judiciaire au 31 janvier 2024
17/01/2024
Report de la décision concernant l’arrêté d’un plan de cession et l’ouverture d’une procédure de liquidation judiciaire au 31 janvier 2024 Paris, France, 17 janvier 2024 – 17h00 CET – Pixium Vision SA (Euronext Growth [...]
Zealand Pharma major shareholder announcement: J O Hambro Capital Management
17/01/2024
Company announcement – No. 4 / 2024 Zealand Pharma major shareholder announcement: J O Hambro Capital Management Copenhagen, Denmark, 17 January 2024 – Zealand Pharma A/S (“Zealand”) (Nasdaq: ZEAL) (CVR-no. 20 04 50 78 [...]
Precipio Signs Distribution Agreement For IV-Cell® and HemeScreen® in Japan
17/01/2024
First order for IV-Cell placed by Major Japanese Laboratory NEW HAVEN, Conn., Jan. 17, 2024 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO) announces it has entered into an [...]
The Emily Program Announces Residential Treatment Expansion to Adults in Columbus, Ohio
17/01/2024
With the addition of adult residential treatment in Columbus, the eating disorder program will offer all levels of care to people of all ages and genders in Central Ohio COLUMBUS, Ohio, Jan. 17, 2024 (GLOBE NEWSWIRE [...]
Trxade health, Inc files its 3Q 10Q
17/01/2024
TAMPA, FL, Jan. 17, 2024 (GLOBE NEWSWIRE) -- TRxADE HEALTH, INC. (NASDAQ: MEDS) (“TRxADE”), a parent company of pharmaceutical business-to-business exchange platform, announced today that it filed its Quarterly Report [...]
Sienna Announces Fourth Quarter 2023 Results Release Date and Conference Call
17/01/2024
MARKHAM, Ontario, Jan. 17, 2024 (GLOBE NEWSWIRE) -- Sienna Senior Living Inc. (“ Sienna ” or the “ Company ”) (TSX: SIA) announced that it will report its 2023 fourth quarter results after market close on Tuesday, [...]
NurExone and Inteligex Kick Off Chronic Spinal Cord Injury Research for Multi-Billion Dollar Healthcare Market
17/01/2024
TORONTO and HAIFA, Israel, Jan. 17, 2024 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (FSE: J90) (NRX.V) (the “ Company ” or “ NurExone ”), a biopharmaceutical company developing biologically-guided exosome [...]
Elicio Therapeutics to Present ELI-002 7P (AMPLIFY-7P) Trial in Progress Poster on Phase 1/2 Study of Lymph Node-Targeted Vaccine at ASCO GI Symposium
17/01/2024
AMPLIFY-7P study builds on preliminary positive findings from the 2-peptide formulation of ELI-002 published in Nature Medicine demonstrating tumor biomarker reduction, with strong T cell responses that correlated with [...]
Kineta Provides Update on its Ongoing Phase 1/2 VISTA-101 Clinical Trial of KVA12123 in Patients with Advanced Solid Tumors
17/01/2024
Cleared First Four Monotherapy Doses and Initial Combination Cohort with No Dose Limiting Toxicities at any Dose Level KVA12123 Monotherapy Demonstrated Dose Proportional Induction of Pro-inflammatory Biomarkers [...]

Pages